These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 9384712)

  • 1. Molecular mechanisms of Bcr-Abl-induced oncogenesis.
    Gishizky ML
    Cytokines Mol Ther; 1996 Dec; 2(4):251-61. PubMed ID: 9384712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular construction of Philadelphia chromosome and its relation to the clinical features].
    Kamada N; Tanaka K; Asou H
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1098-105. PubMed ID: 2053768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathophysiology of chronic myelogenous leukemia.
    Turhan AG; Solary E; Vainchenker W; Dusanter-Fourt I
    Hematol Cell Ther; 1998 Oct; 40(5):217-21. PubMed ID: 9844814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
    Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular basis of chronic granulocytic leukemia: from test-tube to patient].
    Skórski T
    Acta Haematol Pol; 1994; 25(2 Suppl 1):184-91. PubMed ID: 8067203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
    Deininger MW; Vieira S; Mendiola R; Schultheis B; Goldman JM; Melo JV
    Cancer Res; 2000 Apr; 60(7):2049-55. PubMed ID: 10766197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.
    Wu B; Zhou S; Song L; Liu X
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):364-6. PubMed ID: 12408765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling Philadelphia chromosome positive leukemias.
    Wong S; Witte ON
    Oncogene; 2001 Sep; 20(40):5644-59. PubMed ID: 11607816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
    Kharas MG; Fruman DA
    Cancer Res; 2005 Mar; 65(6):2047-53. PubMed ID: 15781610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Philadelphia chromosome 30 years later].
    Lisker R
    Rev Invest Clin; 1992; 44(1):123-30. PubMed ID: 1523343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model mice for BCR/ABL-positive leukemias.
    Honda H; Hirai H
    Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
    Melo JV; Deininger MW
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):545-68, vii-viii. PubMed ID: 15271392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia.
    Costa D; Carrió A; Madrigal I; Arias A; Valera A; Colomer D; Aguilar JL; Teixido M; Camós M; Cervantes F; Campo E
    Cancer Genet Cytogenet; 2006 Apr; 166(1):89-93. PubMed ID: 16616117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
    Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
    Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biology of BCR-ABL.
    Chopra R; Pu QQ; Elefanty AG
    Blood Rev; 1999 Dec; 13(4):211-29. PubMed ID: 10741897
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.